Project Grant R01DA059985
Award Date
8/1/24
Completion Date
5/31/29
Dollars Obligated
$2.2M
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This $650,079 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will support research by Northeastern University to develop novel small-molecule probes targeting the alpha9 nicotinic acetylcholine receptor (α9*-nAChR) for the treatment of chronic inflammatory and neuropathic pain. The key products and services to be delivered under this five-year project...
This $181,675 federal Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant, titled "NICOTINIC MODULATION OF EXCITATORY SYNAPSE DEVELOPMENT IN THE PREFRONTAL CORTEX", will fund research to investigate the mechanisms by which nicotine exposure during pregnancy impacts the maturation of excitatory synapses in the prefrontal cortex. The grant, awarded to the University of Colorado-Denver, will...
This $272,395 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop new methods for targeting the G9A/GLP chromatin-modifying enzyme complex to treat stimulant addiction. The key products and services to be delivered under this 4-year award (04/15/2025 - 03/31/2027) include: Identifying the molecular surfaces and mechanisms that enable specific manipulation of the G9A/GLP enzyme dimers and their...
This federal Project Grant award, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to examine the link between epigenetic processes, mitochondrial function, and drug-seeking behavior in the context of nicotine use disorder. The award, totaling $169,474.00 and spanning August 2024 to July 2029, will be carried out by researchers at the University of Maryland, Baltimore. The key objectives of this research...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to study the neurogenetic mechanisms underlying nicotine and cannabis addiction. The $175,888 award, effective September 1, 2024 through August 31, 2028, will enable the development of novel transcriptome-connectome analysis methods to identify genes associated with changes in brain functional connectivity related to addiction. The...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund research to investigate the role of cholinergic interneurons in the ventral tegmental area on opioid-related behaviors. The $373,181 grant, awarded on July 15, 2024 with a completion date of June 30, 2027, aims to determine whether mu-opioid receptors on cholinergic interneurons contribute to opioid reward, consumption, and withdrawal, and how...
This $399,884 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to identify small molecule compounds that can bind to the GPR26 receptor, which is believed to be a novel target for treating opioid use disorders. The research strategy involves using DNA-encoded library (DEL) screening technology to efficiently test over 125 million novel compounds and identify high-affinity binders to GPR26 that can...
This Project Grant award, with the ID R21DA064023, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The $201,250 award, to be completed between June 1, 2025 and May 31, 2027, will support research by New York University (NYU) to characterize the synaptic organization and connectivity of cholinergic interneurons in the nucleus accumbens core region of the mouse brain. The project aims to use a combination of anatomy,...
This federal Project Grant award of $2,134,928.00 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to develop novel, brain-penetrant, small molecule biased allosteric modulators (BAMs) of the neurotensin receptor 1 (NTSR1) to attenuate relapse to opioid seeking in individuals with opioid use disorder (OUD). The award will validate NTSR1 as a drug target for OUD treatment and discover next-generation BAMs with improved...
This federal Project Grant award for $263,119 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) is focused on developing NLRP3 inhibitors to address HIV-associated neuroinflammation in cocaine use. The key objectives are to computationally design, synthesize, and screen novel analogues of a lead compound, AMS-17, to improve its biological activity and maintain low toxicity. The project involves in vitro and in vivo screening of...